Author:
Yamanaka Ryuya,Zullo Susan A.,Tanaka Ryuichi,Ramsey Jay,Blaese Michael,Xanthopoulos Kleanthis G.
Abstract
Object
The authors investigated immunogene therapy for malignant glioma to determine whether its therapeutic efficacy could be improved.
Methods
Four groups of 203-glioma–bearing mice were treated with injections of phosphate-buffered saline, Semliki Forest virus (SFV)–LacZ, retrovirus vector DFG–interleukin (IL)–12, and SFV-IL12, respectively.
The results indicated that therapeutic immunization with SFV-IL12 prolonged the survival of mice with established tumors. Semliki Forest virus induces apoptotic death to glioma cells, which facilitates the uptake of apoptotic cells by dendritic cells, providing a potential mechanism for enhanced immunogenicity.
Conclusions
Immunogene therapy with IL-12 via SFV may be an excellent candidate for the development of new cancer vaccines.
Publisher
Journal of Neurosurgery Publishing Group (JNSPG)
Subject
Clinical Neurology,General Medicine,Surgery
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献